Understand the role of acquired mutations in resistance to endocrine ... continue to evaluate therapeutics for germline and somatic pathogenic variants. Genomic Signatures in Early-stage ER+ Breast ...

BRCAness refers to tumors that mimic BRCA1/2 mutation behavior, making them vulnerable to DNA-damaging treatments like PARP ...

This trial evaluated the efficacy and safety of Johnson & Johnson’s (J&J) Akeega, which includes Zejula (niraparib), a highly ...

Supplemental Health Care (SHC) released its 2025 Impact Report, highlighting the organization's ongoing dedication to enhancing its impact on behavioral health, education, and healthcare across the ...

There were 22 men with progressive mCRPC enrolled, the median age at enrollment was 66 years (range 52-80), the median PSA at original diagnosis was 82 ng/mL (range 5-3,648), 55% had a Gleason score 9 ...

Seismic Therapeutic, Inc., the machine learning immunology company, today announced the appointment of Sophie Jones, M.D., as the company's Chief Financial Officer, effective June 18, 2025. In this ...

In an interview with Targeted OncologyTM, Massimo Cristofanilli, MD, medical oncologist at the Breast Center at Weill Cornell ...

Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains ...

Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Progression-free survival longer with vepdegestrant than fulvestrant in subgroup with ESR1 mutations ... HER2-negative advanced breast cancer who had received one previous line of cyclin-dependent ...

AACE released clinical guidelines on the diagnosis, management, and surveillance of tumors related to multiple endocrine neoplasia type 1.